Maximum quantity allowed is 999
Please select the quantity
CAS RN: 69304-47-8 | Product Number: B3404
(E)-5-(2-Bromovinyl)-2'-deoxyuridine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- Brivudine
- BVdU
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 100MG |
₩380,300
|
3 | 17 | Contact Us |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | B3404 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__1H__1__3BrN__2O__5 = 333.14 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 69304-47-8 |
| Reaxys Registry Number | 758153 |
| PubChem Substance ID | 87561214 |
| Merck Index (14) | 1378 |
| MDL Number | MFCD00058585 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | +8.0 to +10.0 deg(C=1, MeOH) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 166 °C(dec.) |
| Specific Rotation | 9° (C=1,MeOH) |
GHS
Related Laws:
| RTECS# | YU7355000 |
Transport Information:
| H.S.code* | 2934.99-000 |
Application
Brivudine (BVdU): A Nucleoside Analogue Anti-Herpesvirus Agent
Brivudine (BVdU) is a nucleoside analogue anti-herpesvirus agent, and is often used for treatment of herpes simplex virus-1 (HSV-1) and varicella-zoster virus (VZV) infections. Brivudine blocks the action of DNA polymerases, thus inhibiting viral replication. Brivudine owes its effect to preferential phosphorylation by virus-encoded thymidine kinase to its 5'-diphosphate form. After further conversion to triphosphate form, it acts as an inhibitor or alternate substrate for the viral DNA polymerase. Brivudine is also characterized by a well described fatal drug interaction with antitumor agents such as 5-fluorouracil (5-FU) [F0151] and its prodrugs. This is caused by the main metabolite, bromovinyluracil (BVU), irreversibly inhibiting the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. (The product is for research purpose only.)
References
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent
- On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine
- Discovery and development of BVDU (brivudine) as a therapeutic for the treatment of herpes zoster (a review)
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU) (a review)
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.